API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
ADG126 (muzastotug) is a fully human anti-CTLA-4 SAFEbody. SAFEbody® is company's proprietary precision antibody masking platform designed to enable an antibody to bind its target specifically. It is under development for metastatic microsatellite-stable colorectal cancer.
Lead Product(s): AMP945,Pembrolizumab
Therapeutic Area: Oncology Product Name: ADG126
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2024
Details:
AMP945 (narmafotinib) is a novel focal adhesion kinase (FAK) inhibitor. It is being evaluated in precliical studies for the treatment of patients with pancreatic cancer.
Lead Product(s): AMP945,Calcium Folinate,Fluorouracil
Therapeutic Area: Oncology Product Name: AMP945
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2024
Details:
ADG126 (muzastotug) is a masked anti-CTLA-4 SAFEbody. It is currently being evaluated in phase 1/2 clinical trials for the treatment of microsatellite-stable colorectal cancer.
Lead Product(s): AMP945,Pembrolizumab
Therapeutic Area: Oncology Product Name: ADG126
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Details:
AMP945 (narmafotinib) is an orally bioavailable small molecule with a best-in-class profile. Amplia’s highly selective FAK inhibitor AMP945, when used in combination with FOLFIRINOX, enhances survival in a preclinical model of pancreatic cancer.
Lead Product(s): AMP945,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: AMP945
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 29, 2023
Details:
The research collaboration with CSIRO will help to develop formulations of its small molecule FAK inhibitors, including AMP945 that could be applied topically to wounds and burns to aid healing and reduce scarring.
Lead Product(s): AMP945
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: AMP945
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: CSIRO
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 23, 2023